LUNGPulmonx Corporation

$75M

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$21M+20.9% YoY

Gross Profit

$15M73.7% margin

Operating Income

-$16M-75.2% margin

Net Income

-$15M-73.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$173M

Total Liabilities

$71M

Stockholders' Equity

$101M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$17M	+20.9%
Gross Profit	$15M	$13M	+20.2%
Operating Income	-$16M	-$16M	+5.0%
Net Income	-$15M	-$16M	+5.4%

Geographic Segments

UNITED STATES

$14M67%

EMEA

$6M29%

Asia Pacific

$802,0004%

Other International Geographical Areas

$139,0001%

LUNG Q2 2024 Earnings — Pulmonx Corporation Revenue & Financial Results | Market Cap Arena